SolarWindow Technologies, Inc. (WNDW)

[EricM]

(page two of two)
Please note that the bottom half of the document is very small print so it didn't scan well.




Octifflon Achieves NanoPower Window Breakthrough About Octillion Corp. Octillion Corp., together with its wholly owned subsidiaries, is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging technologies. Through established relationships with universities, research institutions, teaching hospitals and government agencies, we strive to identify technologies and business opportunities on the leading edge of innovation that have the potential of serving significant and unmet market needs. Once a technology has been identified, we fund the research and development activities relating to the technology with the intention of ultimately, if warranted, licensing, commercializing and marketing the subject technology, either through internal resources, collaborative agreements or otherwise. Unique to our business model is the use of established research infrastructure owned by the various institutions we deal with, saving us significant capital which would otherwise be required for such things as land and building acquisition, equipment and furniture purchases, and other incidental start up costs. As a result, we are able to benefit from leading edge research for significantly less than conventional organizations. Among our current research and development activities are the development of 1) a patent-pending technology that could adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing significant transparency or requiring major changes in manufacturing infrastructure, and 2) technologies and products for peripheral and optic nerve damage and nerve regeneration. For additional information, please visit. www.octillioncorp.corn To receive future press releases via email, please visit. http://www.octillioncorp.com/contact.html To view the full HTML text of this release, please visit: http://www.octillioncorp.corn/OCTL 20070604.htmi Leaal Notice Reoard,no ForwrgLLookin, Statemerts No state..nt ho,.,n should be considered an offer or a sol,atation of an offe, 'or the purchase or sale of any securities, This release contains fomardlwking statements that am based upon wrmni xpeLlafio,,s or beliefs, as ell as a number [e-mail].b-tf.t.r..-@t..Altho.ghOOllionCo,p (th.'Company or'Octill@n-)believesthattheexpectationsrallectedinthef@ad-l@kingState@nts.@dtheass.@pt,.n@@,p..whihtheyambasda.-@able,it@ng@. no assumnw that such expe=Wns af,.d assumptions will prce to ha" been correct Fomard-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, am generally dentifiable by use of the ,d5 'may.' 'will," 'should,' 'muld,"expect,' 'anbeipate.' 'estimte."belis@e,"i@tend,' o, 'pm@e@r r the negati- f these ,-ds or the, n these words or wmpamble terminology The mader is cautioned hot to put undue on these fomard-looking statements, as thew statements are sob ct to nu rous factors and uncertainties : ncluding but not limited to adveme emn@ic mndiwns, intense compomion. lack of nwaningful research results, en" of new @petitom and products, adverse fede.1, tat. and I.-I inadequate capital, no.pected osts and pe,sting deficits, i@@a.... in general and d.inistrad@. cost., to-i@sto@ of @t..m @ agreements. technological obsolescence of the C@pany's pmducts, technical problems ith the ConVany's mseach and products, p,im increases for supplies ad components, litigation and ad@i@.Istra6w proceedings involving the Company, the possible ooguisitio. f new businesses or technologies that result in operating losses @ that do hot pefom as anticipated, u,anbcipato, lwses, the pmwble ft.ctuatim and volatility of the Company's operating @suRs financial condition and stock price, l@s incu@d in l@igefing and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage. inability to "n out rewarcn. development and wmmemiali@tion plans, loss or rahm,iwnt of key e@fi@@ and @wmh @ientists. change. in interest rate., i@flatinary f.M@. and th.r spcffic risks. VVe w"ntly ta@a - p,.d,.t.,nt..dd to dign-., treat, past @ -. ." die.m. The tt.-nt. contained in this press release ega,di@g our on going research and development and the s@its attained by us td-date have not been evaluated by the Food and Drug Administmtiw@ The. can be o assur@.ce Uat further esea,ch and development, and for whether clinical trial results, if any. will validate and suppon the esults of our preliminary mwa@h and studies Futh.,, there w. be m that tt,.e nemsmy mgulatoy appm"ls will be obtained w that Odillion ill be able to d@lop commercially @iable products w the basis of its technologies 1,, addition, other factors that could cause actual results to differ ateriady are discussed in the Cmpany's most recent F@ ID-OSS and F@ 10.KSB filings with and Exchange Com@isson, Thew repots and fi[ins may be inspected and copied t the Public Rfe.@- R@ @.i@ti@ed by the tJ.S S@urities & Exchange Commission at 100 F Street. N.E., Washington D.C. 20549. can obtain,nfo@tion about operation of the Public Referen@ Rw by calling the U.S, Securities & Exchange Commission t 1-800-SEC-0330, The U S. S@,ities & Exchange Commission also maintains an Internet site that wnte,ns the f any re@is:,ons to thew fo-ad looking statements that ay be made to reflect the events or ft., the date h ... f to the ...... . f .,.anticipated 2